Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2022-05-17 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞第二届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the first meeting of the second Supervisory Board of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the election of the chairman of the Supervisory Board and confirms the legality and validity of the meeting and its resolutions. There is no financial data, no mention of annual or interim reports, no audit information, no earnings data, and no mention of shareholder votes at a general meeting. The document is a corporate governance announcement related to board-level decisions but specifically about the Supervisory Board meeting resolutions, which fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA. Therefore, the classification is MANG with high confidence.
2022-05-17 Chinese
神州细胞关于公司董事会、监事会完成换届选举暨聘任高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the completion of the board of directors and supervisory board re-election and the appointment of senior management personnel. It details the election results of the board members, committee members, supervisory board members, and the appointment of senior executives. The document references compliance with company law and stock exchange listing rules, and includes biographies of appointed individuals. There is no financial data or report content, but rather a formal announcement of changes in board and management personnel. This fits the category of Board/Management Information (MANG). The document length is 3609 characters, which is relatively short and consistent with an announcement rather than a full report.
2022-05-17 Chinese
神州细胞关于选举第二届监事会职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of a new employee representative supervisor to the company's supervisory board. It includes details about the election process, the term of the supervisory board, and a biography of the elected individual. There are no financial statements, audit information, or regulatory filings related to financial performance. The content focuses on board/management changes, specifically the supervisory board composition. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short but contains substantive information about management changes, not just an announcement of a report or a certification.
2022-05-17 Chinese
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2021年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2021 Annual General Meeting (AGM) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the convening, attendance, voting procedures, and results of the 2021 AGM held in 2022. The document includes detailed voting results on various proposals including the annual report, board reports, financial reports, profit distribution, remuneration plans, auditor appointment, and board elections. The document is not the annual report itself but a legal opinion on the AGM proceedings and voting outcomes. This fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the results of shareholder votes at the AGM. The document length is over 10,000 characters and contains substantive content, not just an announcement of a report publication or a certification. Therefore, the correct classification is DVA with high confidence.
2022-05-17 Chinese
神州细胞2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an announcement of the resolutions from the 2021 Annual General Meeting (AGM) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the date and location of the meeting, attendance, voting results on various proposals including the 2021 annual report, board and supervisory reports, financial statements, profit distribution, remuneration plans, auditor appointment, and board elections. The document is a formal announcement of the voting results and decisions made at the AGM, rather than the full annual report or other detailed reports themselves. It includes detailed voting outcomes and confirms the legality and validity of the meeting and resolutions. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6909 characters) and content support it being a full announcement rather than a brief notice or a report publication announcement.
2022-05-17 Chinese
神州细胞独立董事关于公司第二届董事会第一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the appointment of senior management personnel at Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It references compliance with company law, stock exchange listing rules, and company bylaws. The content focuses on board and senior management appointments and qualifications, with no financial data or report publication. The document length is short (970 characters), and it is not a report but an opinion related to board matters. Therefore, it fits the category of Board/Management Information (MANG).
2022-05-17 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.